DELTA-FLY-PHARMA
Following to the previous information on March 11th, 2024, we are excited to share our latest development status.
We are pleased to announce the protocol for the Phase I/II clinical trial of DFP-10917 combined with Venetoclax (VTX) in patients with acute myeloid leukemia (AML) with prior VTX involved one regimen, which was submitted to the FDA in US on March 8 has been approved by the FDA in US dated April 8, 2024. Accordingly, we can start the Phase I/II combo-study very soon.
The aim for conducting this study is to judge if DFP-10917 combined with VTX is to show superiority to the standard chemotherapy (azacitidine combined with VTX) for AML. This combo-study shall be done by major clinical sites in US like Wake Forest University, expertise with clinical study of novel chemotherapy for AML.
The interim analysis of the Phase III trial of DFP-10917 monotherapy in patients with recurrent or refractory AML is under follow-up for a number of long-term survivors that have a significant impact on the overall survival (OS) analysis.
Please take notice of our own innovative approach for miserable cancer patients and contact with us.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240408884304/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference23.12.2025 12:01:00 CET | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, with a presentation at 7:30 am PST. Live webcasts of these events can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com, https://hkexir.beonemedicines.com, https://sseir.beonemedicines.com. Archived replays will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company based in Switzerland that is discovering and developing innovative treatments that are more accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of nearly 12,000 colleagues spanning six continents, the Company is committed to
I-care Becomes a Unicorn23.12.2025 10:45:00 CET | Press release
The Belgian company has surpassed the billion-euro valuation mark following a €20 million fundraising and refinancing round. I-care announces the completion of a €20 million fundraising and refinancing operation, carried out as a round reserved for existing shareholders and employees. Based on this operation, the group's valuation reaches €1 billion, making I-care a unicorn. "Becoming a unicorn is a symbolic milestone. To achieve this, we chose to invest before reaping the rewards: we bet on AI when few believed in it, we prioritized R&D, and we built our own production unit. These choices were sometimes difficult, but they were essential to staying ahead of the game. Today, our results confirm that this strategy was the right one," explains Fabrice Brion, CEO of I-care. This fundraising round is the first step in a three-phase development plan. Following the “Eau Rouge” operation in 2022, which enabled I-care to become the world leader in predictive maintenance, the company has now se
Liquid Reply Joins the Agentic AI Foundation (AAIF) to Advance Open, Trusted Agentic AI23.12.2025 10:00:00 CET | Press release
Liquid Reply, specialising in platform engineering and cloud-native technologies within the Reply Group, today announced that it has joined the Agentic AI Foundation (AAIF). The newly established foundation was launched under the auspices of the Linux Foundation and provides a neutral, open governance framework for the development of agent-based AI systems. Members collaborate transparently to develop tools, protocols, and specifications that remain available as open-source resources for the global community. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251223604862/en/ Through its membership, Liquid Reply will engage the AAIF community and actively support the establishment of open standards for the next generation of AI-powered applications. By joining the AAIF, Liquid Reply reinforces its commitment to open-source and community-driven innovation, and supports the creation of shared technical foundations for the responsi
Rajant Kinetic Mesh® Proves Subterranean Connectivity During NATO ARRC “Ex AVENGER TRIAD 25” Exercise23.12.2025 10:00:00 CET | Press release
Private, fully mobile mesh delivered resilient, high bandwidth underground comms in a disused mine in Southwest England; ARRC and 22 Signal Regiment explore next steps including a wireless subterranean HQ. Rajant Corporation, the exclusive provider of peer to peer, private Kinetic Mesh® networks consisting of BreadCrumb® wireless nodes powered by InstaMesh® routing, today announced the successful completion of a subterranean communications trial during NATO Allied Rapid Reaction Corps’ (ARRC) primary exercise of the year, Ex AVENGER TRIAD 25, which was conducted in October–November 2025. During the exercise, Rajant provided the communications equipment that delivered robust underground bandwidth in a retired mine in England. The Rajant network operated as a transport-agnostic, multi-bearer networking overlay that unified disparate communication technologies into a single resilient transport fabric, integrating cleanly with existing network transports and mission systems. ARRC users and
Spain’s CESGA Selects IQM and Telefónica to Deploy Advanced Quantum Computing Infrastructure23.12.2025 09:53:00 CET | Press release
IQM will deliver two full-stack quantum computers: a 54-qubits IQM Radiance system and a 5-qubit IQM Spark by June 2026. The systems will support research, skills development, and industrial access to quantum computers across multiple sectors. This will be the first installation of IQM quantum computers in Spain. IQM Quantum Computers, the global leader in deployed, on-premises computers, and Telefónica, a global telecommunications provider, have joined forces to sign a purchase agreement with the Galician Supercomputing Center (CESGA) to install two full-stack quantum computers in Spain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251223742835/en/ Spain’s CESGA selects IQM and Telefónica to deploy advanced quantum computing infrastructure Under the agreement, IQM will deliver and install a 54-qubit IQM Radiance, designed for integration into high-performance computing centres, together with a 5-qubit IQM Spark system ded
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom